PharmaShots | Incisive News in 3 Shots

Subscribe Now

Liver cancer

Roche's Tecentriq (atezolizumab) + Avastin (bevacizumab) Receive the EC's Approval for Unresectable Hepatocellular Carcinoma

Roche's Tecentriq (atezolizumab) + Avastin (bevacizumab) Receive the EC's Approval for Unresectable Hepatocellular Carcinoma

November 3, 2020

Roche's Tecentriq in Combination with Avastin Receives China NMPA's Approval for the Treatment of Unresectable Hepatocellular Carcinoma

Roche's Tecentriq in Combination with Avastin Receives China NMPA's Approval for the Treatment of Unresectable Hepatocellular Carc...

October 30, 2020

AstraZeneca's Imfinzi (durvalumab) + Tremelimumab Receive the US FDA's Orphan Drug Designation for Liver Cancer

AstraZeneca's Imfinzi (durvalumab) + Tremelimumab Receive the US FDA's Orphan Drug Designation for Liver Cancer

January 20, 2020

Shreis Scalene's Cytotron Receives the US FDA's Breakthrough Device Designation for the Treatment of Multiple Cancer Indications

Shreis Scalene's Cytotron Receives the US FDA's Breakthrough Device Designation for the Treatment of Multiple Cancer Indications

October 31, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us